2017. ISPOR European Meeting – Cost-effectiveness of nivolumab in combination with ipilimumab in first-line treatment of advanced melanoma in three European countries using 28-month overall survival from CheckMate 067

Hirst A, Federico Paly V, Diamantogiannis F, Guilmet C, Polanco Sanchez C, Sabater J, et al. Cost-effectiveness of nivolumab in combination with ipilimumab in first-line treatment of advanced melanoma in three European countries using 28-month overall survival from CheckMate 067. Value Health 2017 Oct-Nov;20(9):A432. Presented at: ISPOR 20th European Meeting: November 4-8, 2017; Glasgow, UK.